Table 1.
Clinical characteristics of six case-reports of pregnant women with schizophrenia treated with aripiprazole-LAI and their offspring.
| Mother 1 | Mother 2 | Mother 3 | Mother 4 | Mother 5 | Mother 6 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Maternal and pregnancy outcomes | ||||||||||||
| Year of delivery | 2016 | 2017 | 2019 | 2018 | 2019 | 2019 | ||||||
| Age (years) | 35 | 29 | 35 | 31 | 38 | 30 | ||||||
| Psychiatric diagnosis | Schizophrenia | Schizophrenia Schizotypal personality disorder | Schizophrenia | Schizophrenia | Schizophrenia | Schizophrenia | ||||||
| Psychiatric admission | 2 | 2 | 0 | 0 | 1 | 1 | ||||||
| Previous AP treatment | ziprasidone, risperidone LAI, paliperidone palmitate LAI, fluphenazine decanoate depot | paliperidone palmitate LAI, olanzapine | olanzapine | aripiprazole | paliperidone palmitate LAI | aripiprazole | ||||||
| Parity | Primiparous | Primiparous | Primiparous | Primiparous | Multiparous | Multiparous | ||||||
| Aripiprazole-LAI therapy duration before pregnancy (months) | 32 | 19 | 60 | 36 | 6 | 12 | ||||||
| Aripiprazole-LAI exposure | All pregnancy | All pregnancy | All pregnancy | All pregnancy | All pregnancy | Until 1st trimester (400 mg/28 days) |
||||||
| Aripiprazole-LAI dosage (mg/day) | - 400 mg/ 28 days wk 0–8. - 300 mg/28 days wk 8-delivery |
- 400 mg/28 days wk 0–20. - 300 mg/28 days wk 20-delivery |
- 400 mg/28 days wk 0–5. - 300 mg/28 days wk 5-delivery |
- 160 mg/28 days wk 0-delivery | - 300 mg/28 days wk 0-delivery | - 400 MG/28 days wk 0–8 | ||||||
| BMI | Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post | Pre | Post |
| 29.75 | 28.41 | 25.62 | 24.26 | 32.71 | 38.73 | 23.38 | 24.84 | 24.06 | 26.5 | 25.5 | 27.7 | |
| Weight (g) | 80 | 76.4 | 69.7 | 66 | 87 | 95 | 69 | 73.3 | 77 | 85 | 72 | 78.2 |
| Weight gain in pregnancy—Kg | −3.6 | −3.7 | 8 | 4.3 | 8 | 6.2 | ||||||
| Gestational diabetes | Yes | No | Yes | No | No | No | ||||||
| GA partum (weeks) | 38 + 5 | 31 + 5 | 39 + 6 | 39 + 5 | 39 | 40 | ||||||
| Type of delivery | Eutocic, term birth. | Eutocic, preterm birth | Eutocic, term birth | Eutocic, term birth | Eutocic, term birth | Eutocic, term birth | ||||||
| Neonatal outcomes | ||||||||||||
| Infant sex | Female | Female | Male | Male | Male | Male | ||||||
| Weight (g) (%tile) | 3300 (p50–75) | 1800 (p75–90) | 3140 (p50) | 3102 (p50) | 2940 (p50) | 3400 (p70) | ||||||
| Length (cm) (%tile) | 49 (p25–50) | 44 (p75–90) | 50 (p50) | 53 (p75) | 48.5 (p50) | 53 (p75) | ||||||
| Cranial perimeter (cm) (%tile) | 34.5 (p50–75) | 30 (p50–75) | 36 (p50–75) | 35.8 (p50–75) | 33.1 (p25–50) | 36.2 (p50–75) | ||||||
| Apgar score 1/5 min | 9/10 | 10/10 | 9/10 | 10/10 | 8/10 | 9/10 | ||||||
| Breastfeeding | Yes | No | No | No | No | No | ||||||
| Developmental abnormalities | No | No | No | No | No | No | ||||||
| Status last observation | At 3 years: weight: 12.5 kg (p25–50); height: 92 cm (p50). Normal development | At 2 years: weight: 12.5 kg (p75–90), height: 85 cm (p50); Normal development | At 2 months: weight: 4.870 gr(p70); height: 57 cm (p 25–50.) Normal development | At 2 years: weight: 13.4 Kg (p75); height: 89 cm (p75). Normal development | At 1 year: weight: 10.3 Kg (p50); height: 74.3 cm (p50). Normal development | At 1.5 years: weight: 11.9 kg (p75–90); height: 89 cm (p75) Normal development |
||||||
AP, Antipsychotic; GA Partum, Gestational Age at Partum; LAI, Long-acting injectable; p, percentile; wk, weeks